News

FOX 26 Houston: Diakonos’s Experimental Immunotherapy for Glioblastoma Shows Promising Survival Gains in Early Trials FOX 26 Houston reports on early clinical data from BTIF portfolio company Diakonos Oncology’s investigational dendritic cell immunotherapy for glioblastoma. The report highlights phase I trial results and features a patient currently receiving the treatment. Diakonos’s vaccine therapy — known as Dubodencel or DOC1021 — uses a patient’s own tumor DNA to prime dendritic cells, […] April 16, 2026

Alpheus Medical Initiates Phase 2b Trial of Investigational Therapy for Newly Diagnosed Glioblastoma The company has enrolled 10 patients, marking early momentum in evaluating a novel, non-invasive, drug-centered therapeutic approach to brain cancer treatment. CHANHASSEN, MN, April 9, 2026 – Alpheus Medical, Inc., a private, clinical-stage biotechnology company, today announced the initiation of its Phase 2b randomized controlled trial in newly diagnosed glioblastoma (nGBM) with 10 patients enrolled to date […] April 14, 2026

Trogenix Publishes Glioblastoma Gene Therapy Research in Nature Trogenix Ltd., a Brain Tumor Investment Fund™ (BTIF) portfolio company, has published new preclinical research on its synthetic super-enhancer gene therapy platform for glioblastoma in the journal Nature. The paper describes the technology behind Trogenix’s lead program, which the company plans to advance into a first-in-human clinical trial later this year. The full paper is available […] April 13, 2026

Forbes: “Clinical Trial For Brain Cancer Treatment Has Promising Results” Brain Tumor Investment Fund (BTIF) portfolio company, Alpheus Medical, was recently featured in an article on the magazine Forbes’s website. The article highlights encouraging results from an ongoing clinical trial evaluating Alpheus’s LIDU® system in patients with glioblastoma. This novel therapeutic approach – known as sonodynamic therapy – uses low-intensity ultrasound to activate a tumor-targeting […] April 2, 2026

Cordance Medical Announces an Oversubscribed $8M Seed Financing to Advance Focused Ultrasound Platform for Brain Disease Treatment Cordance Medical, a pioneer in noninvasive focused ultrasound technology for brain disease treatment, today announced an oversubscribed seed financing round led by Sonder Capital. The round surpassed its $8M target and included participation from existing and new investors, including Shanda Grab Ventures, Angel Physician’s Fund, SmartGateVC, and R42. The Sontag Foundation Innovation Fund, a subsidiary of […] November 24, 2025